DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Yujin | ko |
dc.contributor.author | Lee, Seojung | ko |
dc.contributor.author | Jon, Sangyong | ko |
dc.date.accessioned | 2024-09-05T09:00:22Z | - |
dc.date.available | 2024-09-05T09:00:22Z | - |
dc.date.created | 2023-11-27 | - |
dc.date.issued | 2024-03 | - |
dc.identifier.citation | ADVANCED HEALTHCARE MATERIALS, v.13, no.6 | - |
dc.identifier.issn | 2192-2640 | - |
dc.identifier.uri | http://hdl.handle.net/10203/322696 | - |
dc.description.abstract | Tumor-associated macrophages (TAMs)-representative immune-suppressive cells in the tumor microenvironment (TME)-are known to promote tumor progression and metastasis, and thus are considered an attractive target for cancer therapy. However, current TAM-targeting strategies are insufficient to result in robust antitumor efficacy. Here, a small lipid nanoparticle encapsulating immunostimulatory CpG oligodeoxynucleotides (SLNP@CpG) is reported as a new immunotherapeutic modality that can reprogram TAMs and further bridge innate-to-adaptive immunity. It is found that SLNP@CpG treatment enhances macrophage-mediated phagocytosis of cancer cells and tumor antigen cross-presentation, and skews the polarization state of macrophages in vitro. Intratumoral injection of SLNP@CpG into an established murine E.G7-OVA tumor model significantly suppresses tumor growth and considerably prolongs survival, completely eradicating tumors in 83.3% of mice. Furthermore, tumor-free mice resist rechallenge with E.G7-OVA cancer cells through induction of immunological memory and long-term antitumor immunity. SLNP@CpG even exerts antitumor efficacy in an aggressive B16-F10 melanoma model by remodeling TME toward immune stimulation and tumor elimination. These findings suggest that, by modulating the function of TAMs and reshaping an immunosuppressive TME, the SLNP@CpG nanomedicine developed here may become a promising immunotherapeutic option applicable to a variety of tumors.,A liposome-based nanomedicine encapsulating an immune-stimulatory CpG (SLNP@CpG) for tumor-associated macrophage (TAM)-reprogramming immunotherapy is developed in this study. Liposomal delivery of CpG via local (intratumoral) treatment reprograms TAMs and also reshapes the immunosuppressive tumor microenvironment, leading to antitumor immunity and long-term memory responses. This nanomedicine could be a promising immunotherapeutic option applicable to a variety of tumors.image, | - |
dc.language | English | - |
dc.publisher | WILEY | - |
dc.title | Liposomal Delivery of an Immunostimulatory CpG Induces Robust Antitumor Immunity and Long-Term Immune Memory by Reprogramming Tumor-Associated Macrophages | - |
dc.type | Article | - |
dc.identifier.wosid | 001102491900001 | - |
dc.identifier.scopusid | 2-s2.0-85176606049 | - |
dc.type.rims | ART | - |
dc.citation.volume | 13 | - |
dc.citation.issue | 6 | - |
dc.citation.publicationname | ADVANCED HEALTHCARE MATERIALS | - |
dc.identifier.doi | 10.1002/adhm.202300549 | - |
dc.contributor.localauthor | Jon, Sangyong | - |
dc.description.isOpenAccess | N | - |
dc.type.journalArticle | Article | - |
dc.subject.keywordAuthor | CpG | - |
dc.subject.keywordAuthor | liposomes | - |
dc.subject.keywordAuthor | nanoparticles | - |
dc.subject.keywordAuthor | tumor-associated macrophages | - |
dc.subject.keywordAuthor | cancer immunotherapy | - |
dc.subject.keywordPlus | NANOPARTICLES | - |
dc.subject.keywordPlus | COOPERATION | - |
dc.subject.keywordPlus | RECEPTOR | - |
dc.subject.keywordPlus | CD47 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.